drugset / Trial / NCT04169178
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
Non-randomizedSequentialOpen-labelTreatment
Summary
A mutilpe-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX55 in patients with advanced solid tumors overexpressing/Mutation/Amplification cMET after failure of standard of care.
Timeline
- Start
- 2020-03-03
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX55 | Monoclonal antibody | 2.5 mg/kg | — |
| Subject | HLX55 | Monoclonal antibody | 5 mg/kg | — |
| Subject | HLX55 | Monoclonal antibody | 15 mg/kg | — |
| Subject | HLX55 | Monoclonal antibody | 25 mg/kg | — |